Related Experiment Video
Updated: Jun 19, 2026
06:19
Galleria mellonella as an Antimicrobial Screening Model
Published on: October 11, 2024
Barminomycin, a model for the development of new anthracyclines
K Kimura1, D M S Spencer, R Bilardi
1Department of Biological Chemistry and Food Science, Iwate University, Morioka, Japan.
Anti-Cancer Agents in Medicinal Chemistry
|October 8, 2009
Summary
Barminomycin, an anthracycline anticancer agent, exhibits 1,000-fold greater cytotoxicity than doxorubicin due to its unique imine form. Its DNA adducts are highly stable and essentially irreversible, offering insights for new drug design.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Molecular Biology
Background:
- Barminomycin is an anthracycline anticancer agent.
- It was discovered as a complex with DNA/RNA (SN-07).
- Its structure features a unique eight-membered ring with a carbinolamine/imine group.
Purpose of the Study:
- To investigate the exceptional activity and DNA binding of barminomycin.
- To compare barminomycin-DNA adducts with doxorubicin-DNA adducts.
- To provide insights for designing novel, stable anthracycline derivatives.
Main Methods:
- Nuclease digestion to isolate barminomycin.
- Analysis of DNA adduct formation and stability.
- 3D modeling of the barminomycin-DNA complex using NOE constraints.
Main Results:
- Barminomycin is 1,000-fold more cytotoxic than doxorubicin.
- It forms highly selective and irreversible adducts with DNA at 5"-GC-3" sequences.
- Barminomycin-DNA adducts are significantly more stable than doxorubicin-DNA adducts due to protected linkage.
Conclusions:
- The imine group in barminomycin confers exceptional anticancer activity and DNA binding stability.
- Barminomycin's irreversible DNA adducts offer a model for developing more effective and stable anthracycline therapies.
- Understanding barminomycin-DNA interactions can guide the design of next-generation anticancer agents.
Related Concept Videos
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...